Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06569290 · ClinicalTrials.gov registry record · NA
Refinement and Testing of Recruitment Methodology for Behavioral Medication Adherence Interventions Using Behavioral Science-based Approaches
A NA study of Diabetes and Medication Adherence, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 584
- Enrollment target
- 1
- Study location
NCT06569290: Recruiting NA study of Diabetes and Medication Adherence, sponsored by Brigham and Women's Hospital.
NCT06569290 is a NA study of Diabetes and Medication Adherence that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 584 participants, below the 3,027-participant average among 338 other Diabetes trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06569290, a NA study of Diabetes and Medication Adherence, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 584 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching goal of the proposed research is to prepare the clinical pharmacist intervention for sustainable implementation and dissemination. Because the effectiveness of the intervention has already been demonstrated in a NIH Stage Model IV trial, the investigators propose an Effectiveness-Implementation Type 3 Hybrid design, in which the primary focus is on testing different implementation methods, while secondarily observing clinical effects. The investigators' overarching hypothesis is to identify the most impactful elements of a behavioral theory-informed recruitment approach, which can be replicable across clinical settings. Accordingly, the investigators propose to perform testing of a behaviorally-informed recruitment approaches in a community-based setting. Like the previous Tele-Pharmacy Intervention to Improve Treatment Adherence (STIC2IT) trial (NCT02512276), participants will be English or Spanish speaking adults ≥18 years of age identified through the electronic health record (EHR) as having poor disease control and/or poor medication adherence for diabetes. The primary care physicians of eligible patients identified through the EHR will be contacted to opt-out any patients they wish not to be included. Patients will then be randomized to each of the following conditions, such that there will be 8 total arms: (1) inclusion of a mailer primer (yes/no), (2) the most successful recruitment letter from the preliminary study using prospect theory (versus the control letter), and (3) intensity of the intervention outreach (4 calls vs. 2 calls). The investigators plan to enroll 584 participants who meet the inclusion criteria, with 73 patients per each of the 8 study arms. Patients across all arms who agree to be scheduled will receive an appointment with one of the clinical pharmacists within the established BMC pharmacist program. The primary outcome will be completion of a clinical pharmacist appointment within 8 weeks after randomization. Key secon
Primary Outcome
rate of participants who completed their clinical pharmacist consultation
Conditions Studied
Interventions
- BEHAVIORAL Primer postcard
- BEHAVIORAL Control recruitment letter
- BEHAVIORAL Behavioral theory-informed recruitment letter (prospect theory)
- BEHAVIORAL 2 phone calls
- BEHAVIORAL 4 phone calls
Study Locations (1)
Massachusetts
- Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 584 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2026-04-30 |
| Phase | NA |
What NCT06569290 shows while recruiting
NCT06569290 is an interventional study that assigns participants to a tested intervention. The registered 584 participants enrollment target is mid-sized for trials with a published cap, below the 3,027-participant average among 338 other Diabetes trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Diabetes appearing as the primary indexed condition, and to 5 interventions - of which Primer postcard is the first listed.
NCT06569290 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06569290 about?
NCT06569290 is a clinical study titled "Refinement and Testing of Recruitment Methodology for Behavioral Medication Adherence Interventions Using Behavioral Science-based Approaches". The overarching goal of the proposed research is to prepare the clinical pharmacist intervention for sustainable implementation and dissemination. Because the effectiveness of the intervention has already been demonstrated in a NIH Stage Model IV trial, the investigators propose an Effectiveness-Imp...
What is the current status of trial NCT06569290?
This trial is currently recruiting. It is a NA study. The enrollment target is 584 participants. The study started on 2025-03-03. Estimated completion is 2026-04-30.
What conditions does trial NCT06569290 study?
This clinical trial studies the following conditions: Diabetes, Medication Adherence, Pharmacist-Patient Relations.
What interventions are being tested in trial NCT06569290?
The interventions under investigation include: Primer postcard (BEHAVIORAL), Control recruitment letter (BEHAVIORAL), Behavioral theory-informed recruitment letter (prospect theory) (BEHAVIORAL), 2 phone calls (BEHAVIORAL), 4 phone calls (BEHAVIORAL).
Who is sponsoring clinical trial NCT06569290?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06569290 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06569290's enrollment target sits among peer trials
584 67th of 338 higher than 272 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
Bringing Advocacy Via Digital Guide to the Emergency Department (Project BADGE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03840083 · 584 participants · NA
Sleep-dependent Learning in Aging
- NCT04984291 · 584 participants · NA
Zimmer Biomet Shoulder Arthroplasty PMCF
- NCT05983757 · 584 participants · NA
Combined Thrombectomy for Distal MediUm Vessel Occlusion StroKe
- NCT02803957 · 585 participants · NA
Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI